European Life Sciences Survey Shows Need for More Detailed Customer Data to Improve Healthcare Professional Interactions
New research released by Veeva Systems at eyeforpharma Barcelona reveals the need for more detailed customer profile and email data, as the life sciences industry strives to improve the effectiveness of customer engagements. Results from the Veeva 2016 European Customer Data Survey show that a majority (70%) of companies are looking for greater customer segmentation data to deliver personalized multichannel communications.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170315005248/en/
Life sciences companies can increase reach and deliver more relevant, tailored information to physicians through digital engagement. In addition, healthcare professionals (HCPs) can interact with field reps through the online channels and mobile devices they prefer. Quality customer data is foundational for effective digital engagement, and yet findings from the survey show gaps in customer data quality.
Less than half (40%) of respondents are satisfied that their customer data provides a complete and real-time view, despite nearly three-quarters (73%) citing a complete and real-time view as a top customer data priority. Commercial operations and marketing have the lowest satisfaction, with less than one-third of commercial operations (32%) and marketing (31%) respondents satisfied that they have a complete and real-time customer view.
Consequently, the need for improved data quality is on the top of the corporate agenda for a majority of life sciences companies. More than three-quarters (78%) of respondents say they either have data quality improvement initiatives in place or will do so within two years. Looking beyond what their data provider offers today, more than half (58%) cite email data as a key future requirement and nearly half (49%) identify KOL profile data as priority.
“There is a significant opportunity for the life sciences industry to increase the effectiveness of customer engagements, fueled by quality customer data, to deliver the right content at the right time through the right channel,” said Guillaume Roussel, director of strategy, Veeva OpenData, Europe. “Multichannel customer engagement is at the heart of successful commercial strategies, and the transition of customer data will allow life sciences companies to improve customer interactions.”
The Veeva 2016 European Customer Data Survey examines the current state of data quality within life sciences companies across Europe. The findings represent the experiences and opinions of more than 80 life sciences decision makers across all of the major European markets, with respondents primarily from France, Germany, Italy, Spain, and UK.
Download the survey executive summary: veeva.com/eu/datasurvey
View the infographic on commercial operations data requirements: veeva.com/eu/commopspotlight
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @Veeva_EU on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit www.veeva.com/eu .
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s filing on Form 10-Q for the period ended October 31, 2016. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2017 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo
are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ASTRAZENECA10.12.2017 23:47 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
NJ-CELGENE/BLUEBIRD-BIO10.12.2017 16:32 | pressemeddelelse
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
GA-GILEAD-SCIENCES/KITE10.12.2017 16:32 | pressemeddelelse
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
MA-TAKEDA/SEATTLE10.12.2017 14:02 | pressemeddelelse
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
ASTRAZENECA9.12.2017 19:02 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
JANSSEN9.12.2017 18:21 | pressemeddelelse
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum